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Crescentic glomerulonephritis (GN) in Wistar-Kyoto rats
progresses to lethal kidney failure by macrophage
(M/)-mediated mechanisms. M/s in nephritic glomeruli
express adenosine A2A receptors (A2ARs), the activation of
which suppresses inflammation. Here, we pharmacologically
activated the A2ARs with a selective agonist, CGS 21680, and
inactivated them with a selective antagonist, ZM241385, to
test the effects on established GN. When activation was
delayed until antiglomerular basement membrane GN and
extracellular matrix deposition were established, glomerular
M/ infiltration was reduced by 83%. There was also a marked
improvement in glomerular lesion histology, as well as
decreased proteinuria. A2AR activation significantly reduced
type I, III, and IV collagen deposition, and E-cadherin
expression was restored in association with a reduction of
a-smooth muscle actin-positive myofibroblasts in the
interstitium and glomeruli. In contrast, pharmacological
inactivation of A2ARs increased glomerular crescent
formation, type I, III, and IV collagen expression, and
enhanced E-cadherin loss. Activation of A2ARs suppressed
the expression of the M/-linked glomerular damage
mediators, transforming growth factor-b, osteopontin-1,
thrombospondin-1, and tissue inhibitor of metalloproteinase-1.
Thus, A2AR activation can arrest GN and prevent progressive
fibrosis in established pathological lesions.
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Blocking the inflammation and chronic progressive fibrosis
in the kidney induced by glomerulonephritis (GN) remains
an unsolved problem. As treatment is initiated after the
disease process has developed, the ideal treatment would not
only prevent progression but might also help stimulate repair
and resolution of the inflammation and fibrosis.
In patients with anti-glomerular basement membrane
(GBM) GN, macrophage (Mf) infiltration into glomeruli
was demonstrated 430 years ago.1 In fact, accumulation of
Mfs in glomeruli and interstitium occurs in most types of
GN, as well as in other experimental models of kidney
disease, irrespective of whether the initial kidney insult is
mediated by immune or nonimmune mechanisms.2–4 Anti-
GBM GN is a rapidly progressive glomerular disease in which
inflammation in the glomerulus progresses rapidly into
chronic kidney disease.5,6 In anti-GBM GN, there is an
association between Mf accumulation and the development
of progressive kidney injury.7 Mfs can be found in the
crescents developing in progressive GN and they are linked to
the irreversible scarring that leads to end-stage kidney
failure.4,6,8 The ability of Mfs to secrete a wide range of
factors causing tissue injury suggests that these cells actively
mediate kidney injury. For example, depletion of Mfs with
antibodies or treatment with antibodies against Mf-attract-
ing chemokines can reduce the glomerular injury and
proteinuria in anti-GBM GN.9–11
The mechanism by which Mfs cause kidney damage
includes increased tissue inhibitor of matrix metallo-
proteinase-1 (TIMP-1) and collagen expression.9 Whether
the expression of other mediators also occurs has not been
extensively studied.
These responses could affect the development of fibrosis in
the kidney because increasing synthesis and/or decreased
degradation of extracellular matrix (ECM) leads to stabiliza-
tion of ECM. Key mediators that promote ECM and fibrosis
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include transforming growth factor-b1 (TGF-b1), osteopon-
tin-1 (OPN-1), thrombospondin-1 (TSP-1, which activates
latent TGF-b1), and tissue inhibitors of matrix metallopro-
teinases (MMPs). Notably, all of these molecules are
produced by Mfs.12,13
How might these inflammatory processes be blocked?
Activation of the adenosine 2A receptor (A2AR), present on
most bone marrow-derived cells, was found to attenuate
inflammation in ischemia–reperfusion injury, diabetic ne-
phropathy, autoimmune disorders, and sepsis.14–17 Moreover,
agonists of A2AR can improve wound healing.
18 We have
found that A2AR is expressed on Mfs isolated from nephritic
glomeruli. When we activated A2AR in rats with anti-GBM
GN at the same day of the induction of the disease, we found
attenuation of inflammation and the degree of kidney injury.
Conversely, inhibition of A2AR worsened the disease.
16 These
results prompted us to explore whether activation of A2AR
could have potential therapeutic efficacy by arresting or
reversing established GN and to prevent its progression to
advanced kidney disease.
RESULTS
A2AR activation arrests established GN
We modulated A2AR activity in established glomerular
disease. Treatment was started at day 14 after the injec-
tion of anti-GBM antibody (Ab) and the rats were killed
at day 20.
In control rats, anti-GBM GN induced glomerular
hypercellularity with necrotizing lesions and crescentic
formation. In contrast, the degree of kidney injury was
markedly reduced in rats treated with A2AR agonist at day 14
after the infusion of the anti-GBM Ab. The glomerular
hypercellularity, the frequency of necrotizing lesions, and
crescent formation were reduced 48% (from 1.34 to 0.070,
Po0.01), 89.98% (from 11.56 to 1.18%, Po0.01), and 30%
(from 56.7 to 39.3%, Po0.05), respectively (Figure 1). In
contrast, A2AR inhibition resulted in a higher frequency of
crescentic glomeruli (56.7 vs 71.6% of glomeruli, Po0.02)
compared with control rats (Figure 1). A2AR activation also
prevented proteinuria at 24 h following the administration of
the A2AR agonist. Notably, the decrease in proteinuria was
sustained for the duration of treatment. In sharp contrast,
administration of the A2AR antagonist increased proteinuria
at days 15 and 17 (Figure 2a). As a result of the attenuation of
inflammatory lesions in the kidney, normal function was
maintained in anti-GBM GN rats treated with A2AR agonist
compared with the control group (Po0.03; Figure 2b). Our
results indicate that selective activation of A2AR during the
progressive phase of anti-GBM GN arrests kidney damage
and proteinuria.
Kidney protection in GN by A2AR activation is associated with
reduced M/ infiltration
To understand the mechanism whereby A2AR activation
suppresses kidney injury, we examined cellular infiltrates in
the kidney. As shown in Figure 1, there was a prominent
accumulation of ED1þ Mfs in the glomeruli and inter-
stitium of untreated rats with GN. A2AR agonist treatment
attenuated the infiltration of Mfs by 83% in the glomeruli
(17.7±0.86 vs 3.14±0.133, Po0.0001) and 72% in the
interstitium (36.7±2.1 vs 10.3±0.77, Po0.0001) compared
with results in untreated group. However, Mf infiltration
was not completely suppressed by A2AR agonist (A2AR treated
3.14±0.133 vs normal 1.75±0.138, Po0.01; Figure 1). In
contrast, A2AR inactivation did not decrease Mf infiltration.
CD8þ cells were not detected at this time of the disease (their
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Figure 1 |Adenosine 2A receptor (A2AR) activation at day 14 after injection of anti-glomerular basement membrane (GBM)
antibody (Ab) attenuates glomerular injury and macrophage infiltration: periodic acid-Schiff (PAS) staining and
immunohistochemistry stained for ED1þ monocytes/macrophages of kidney sections of rats with anti-GBM glomerulonephritis
(GN; n¼ 6 in each group). In control rats there was severe glomerular hypercellularity, necrotizing lesion, crescent formation, and
prominent macrophage infiltration. In rats treated with A2AR agonist, glomerular injury and macrophage infiltration were significantly
attenuated. Worsening of glomerular injury with increased crescent formation was observed in rats treated with A2AR antagonist.
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peak influx is at day 3 after the induction of the disease and
decreased thereafter10,16,19), and few CD4þT cells were
observed during GN with no difference among the groups
(data not shown). Thus, selective activation of A2AR blocks
Mf infiltration, providing a mechanism for the protection of
the kidney from progressive GN.
Reduced M/ infiltration by A2AR agonist correlates with the
suppression of MDC/CCL22 chemokine expression
We determined if the attenuation of Mf infiltration could be
attributed to Mf apoptosis or to reduced chemotactic rec-
ruitment into the kidney. Immunostaining for Mfs and TdT-
mediated dUTP nick end labeling (TUNEL) assay using serial
sections demonstrated higher number of TUNEL-positive
cells in the kidneys of untreated group compared with the
A2AR-agonist-treated group (Po0.01, Figure 3a and b).
However, A2AR activation suppressed macrophage-derived
chemokine (MDC)/chemokine (C-C motif) ligand 22
(CCL22) expression, one of the main chemokines expressed
during the progressive phase of anti-GBM GN (Figure 3c).10
A2AR inactivation restored MDC/CCL22 expression. These
results suggest that A2AR activation reduces Mf recruitment
through inhibition of MDC/CCL22 expression.
A2AR activation decreases collagen deposition
Control rats showed progressive deposition of type I and III
collagens at day 20 after the injection of anti-GBM Ab
(Figures 4 and 5). Pharmacological activation of A2AR
significantly reduced collagen (Col) I accumulation compared
with untreated GN rats (4.6±1.03 vs 7.7±1.0% area, Po0.01;
Figures 4h and i and 5). A2AR activation also reduced the
expression of Col III (6.95±1.8 vs 13.16±2.2% area, Po0.01
in untreated rats) (Figures 4m and n and 5). Importantly, the
A2AR agonist reduced Col III to levels lower than that observed
in untreated rats at day 14 after the injection of anti-GBM Ab,
documenting a reversal in the fibrosis (Figures 4l–m and 5,
Po0.05). In contrast, the A2AR antagonist significantly
enhanced Col I and Col III expression at day 20 (Figures 4i, j,
n, and o and 5).
At day 20, the deposition of collagen type IV was
also markedly reduced by A2AR activation compared with
control rats. More interestingly, morphometric analysis
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Figure 2 | Effects of adenosine A2 receptor (A2AR) activation and inactivation on urinary protein excretion and serum creatinine.
(a) Determination of proteinuria (mg per 24 h) from Wistar-Kyoto (WKY) rats with anti-glomerular basement membrane (GBM)
glomerulonephritis (GN) after treatment with vehicle, adenosine 2A receptor (A2AR) agonist, or A2AR antagonist (antag). A2AR agonist
blocked and A2AR antagonist increased proteinuria. *Po0.01 vs control, **Po0.05 vs control, dPo0.01 vs A2AR antagonist.
(b) Serum creatinine (SCr; mg/dl). The SCr levels in A2AR-agonist-treated group were not different from those of normal rats.
*Po0.05 vs normal, **Po0.03 vs control, dPo0.01 vs A2AR antagonist, &Po0.01 vs normal.
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Figure 3 |Detection of apoptotic cells by TdT-mediated dUTP nick end labeling (TUNEL) assay and determination of macrophage-
derived chemokine/chemokine (C-C motif) ligand 22 (MDC/CCL22) expression by RNase protection assay. (a, b) Immunostaining of
macrophages and TUNEL assay demonstrated increased apoptosis in the glomeruli and tubulointerstitium in the control group.
(c) MDC/CCL22 mRNA expression was suppressed by adenosine 2A receptor (A2AR) agonist. Probes contain polylinker regions and are
longer than the protected bands. Rat ribosomal L-32 gene was used as a housekeeping gene.
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demonstrated less collagen type IV in A2AR-agonist-treated
rats when compared with results from untreated rats at day
14 after induction of GN (17.8±2.3 vs 22.2±3.03% area;
Po0.05, see Figures 4b–d and 5), again demonstrating
reversal of injury. In contrast, A2AR antagonist significantly
increased Col IV deposition at day 20 compared with control
rats (Figures 4d and e and 5). Our results suggest that A2AR
activation will inhibit kidney fibrosis by modulating ECM
deposition, potentially by suppressing Mf infiltration. Again,
the degree of the reduction in collagen deposition suggests
that A2AR activation will arrest kidney disease progression
and might lead to reversal of kidney fibrosis.
A2AR activation reduces a-smooth muscle actin (a-SMA)
deposition and restores E-cadherin expression
As alterations of E-cadherin and a-SMA expression have been
shown to have a role in the development of kidney fibrosis, we
investigated if A2AR activation affects these cellular events.
20 In
untreated GN rats, E-cadherin expression was reduced at day 20
after injection of the anti-GBM Ab (Figure 4s). E-cadherin
expression was restored by A2AR activation at day 20 after the
Ab injection (Figures 4r and 5). In contrast, A2AR inactivation
enhanced E-cadherin loss (Figure 4s and t and 5). A2AR
activation reduced the appearance of a-SMA-positive cells in
glomeruli and tubules at day 20 after the injection of anti-GBM
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Figure 4 | Effects of adenosine 2A receptor (A2AR) activation and inactivation on collagen (Col) I, Col III, Col IV, E-cadherin,
and a-smooth muscle actin (a-SMA) deposition. Normal controls (a, f, k, p, u), control group at day 14 (D14) after the injection of
anti-glomerular basement membrane (GBM) antibody (Ab; b, g, l, q, v), A2AR-agonist-treated group (c, h, m, r, w) at day 20 (D20),
control group at day 20 after the induction of anti-GBM glomerulonephritis (GN; d, i, n, s, x), and A2AR-antagonist-treated group at day 20
(e, j, o, t, y). At day 20, A2AR agonist treatment reduced Col IV, Col I, and Col III deposition (c, h, m). A2AR agonist reversed Col IV and
Col III deposition as Col IV and Col III expression in A2AR-agonist-treated group was significantly lower at day 20 than in the control
group at day 14 (b, c, l, m). A2AR antagonist significantly enhanced Col IV, Col I, and Col III deposition (e, j, o). At day 20, A2AR agonist
treatment restored E-cadherin expression (r, s) and A2AR antagonist enhanced E-cadherin loss compared with control group (s, t). A2AR
agonist reduced appearance of a-SMA-positive cells in the kidney at day 20 (w, x). Tubular a-SMA was significantly reversed by A2AR agonist
(v, w, x). In contrast, A2AR antagonist increased the expression of a-SMA in both glomeruli and tubules (x, y).
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Figure 5 |Morphometric analysis of collagen (Col) IV, Col I, Col III, E-cadherin, and a-smooth muscle actin (a-SMA) expression
in the kidneys by computer-assisted image quantification (Optimas 6.5, Optimas, Bothell, WA). Results from normal kidneys,
glomerulonephritic kidneys from day 14 (D14) and day 20 (D20) after the injection of anti-glomerular basement membrane (GBM)
antibody (Ab), kidneys from rats with anti-GBM glomerulonephritis (GN) treated with adenosine 2A receptor (A2AR) agonist (CGS) or
A2AR antagonist (ZM) are shown. Twenty fields were analyzed at magnifications of  400 (collagens) or  200 (E-cadherin and a-SMA).
Data were expressed as mean±s.d. percent (%) area (n¼ 6 in each group).
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Figure 6 |RNase protection assay for transforming growth factor-b1 (TGF-b), tissue inhibitor of matrix metalloproteinase-1
(TIMP-1), thrombospondin-1 (TSP-1), and osteopontin-1 (OPN-1). Macrophages isolated from nephritic glomeruli at day 20 (D20)
express TGF-b, TIMP-1, TSP-1, and OPN-1 (a, b). In established glomerulonephritis (GN), profibrotic molecules TSP-1, OPN-1, and TGF-b were
highly induced in whole kidneys. Adenosine 2A receptor (A2AR) agonist treatment prevented the induction of TSP-1 and significantly
reduced the expression of OPN-1 and TGF-b in the kidney (c, d). Probes contain polylinker regions and are longer than the protected bands.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GM-CSF, granulocyte macrophage-colony stimulating factor; IFNb, interferon b; IFNg,
interferon g; Ltb, lymphotoxin b; L32, ribosomal protein L32; MIF, macrophage migration inhibitory factor; TGFb1, transforming growth
factor-b1; TGFb2, transforming growth factor-b2; TGFb3, transforming growth factor-b3; TNFa, tumor necrosis factor a; TNFb, tumor
necrosis factor b.
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Ab compared with untreated rats (Figures 4w and x and 5).
In contrast, A2AR inhibition significantly increased a-SMA
expression (Figures 4x and y and 5). We also examined the
expression of E-cadherin and a-SMA in the whole kidney by
immunoblotting; the results correlated with those determined
by immunohistochemistry (data not shown).
A2AR agonist modulates the expression of profibrotic
mediators
We determined mRNA levels of genes that could be
responsible for producing kidney fibrosis. These included
cytokines/growth factors expressed in Mfs isolated from
nephritic glomeruli. Using RNase protection assay, we found
that Mfs infiltrating the nephritic glomeruli express TGF-b1,
TSP-1, OPN, and TIMP-1 (Figure 6a and b). We also
investigated the difference in the expression of these
profibrotic molecules in whole kidney following treatment
of rats with anti-GBM GN with either the A2AR agonist or
the A2AR antagonist. We found increased expression of
OPN-1, TSP-1, and TGF-b1 in the whole kidneys of rats with
anti-GBM GN (Figure 6c and d), and activation of A2AR
markedly decreased the expression of OPN-1 and prevented
the induction of TSP-1 and TGF-b1 (Figure 6c and d).
In contrast, A2AR inactivation restored TGF-b1 expression
(Figure 6d) and increased the expression of TSP-1 and OPN
(data not shown). The mRNA levels of bone morphogenic
protein-7 (Supplementary Figure S1 online), vascular
endothelial growth factor, and hepatocyte growth factor were
not modified with the treatment (data not shown).
A2AR activation changes matrix turnover
To probe why A2AR activation prevented kidney fibrosis, we
also examined mRNA expression of MMP-2 and TIMP-1. In
whole kidney of untreated GN rats or GN rats treated with
the A2AR agonist or antagonist, the transcript levels of MMP-
2 were increased and there were no significant differences
among the three groups (Figure 7). In contrast, the MMP-2
inhibitor TIMP-1 transcript was significantly decreased
in A2AR-treated group (Figure 7). These results suggest
that MMP-2 could increase ECM degradation upon A2AR
activation because TIMP-1 is downregulated.
Effect of A2AR agonist and antagonist on M/ polarization
We investigated if A2AR activation modulates Mf polariza-
tion from a classically activated M1 phenotype to alterna-
tively activated M2 cells. In the control group, most of the
Mfs were identified as M1 Mfs (CD169þ cells) in the
glomeruli and interstitium (74.3 and 69.75%, respectively);
interestingly, many Mfs were also M2 phenotype (CD163þ
cells; 64% in the glomeruli and 50.68% in the interstitium;
Figure 8). In A2AR-agonist-treated group, 63.7% of the Mfs
into the glomeruli and 66.01% in the interstitium were M1
Mfs, whereas 36.5 and 47.5% were M2 Mfs in the glomeruli
and interstitium. Notably, in A2AR-antagonist-treated rats,
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Figure 7 | Selective activation of adenosine 2A receptor (A2AR) modulates genes that affect matrix turnover as determined by
RNase protection assay. (a) In anti-glomerular basement membrane (GBM) glomerulonephritis (GN), matrix metalloproteinase-2 (MMP-2)
was expressed and was unaffected by A2AR agonist or A2AR antagonist (antag). (b) Increased MMP-2 mRNA expression was associated with
an induction in the expression of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in control rats and in A2AR-antagonist-treated rats.
In contrast, a significant reduction of TIMP-1 expression was observed in A2AR-agonist-treated rats. *Po0.01 vs control. Probes contain
polylinker regions and are longer than the protected bands.
Kidney International (2011) 80, 378–388 383
GE Garcia et al.: Adenosine A2A receptors arrest kidney disease o r ig ina l a r t i c l e
most of the Mfs at both the glomeruli and interstitium were
M1 phenotype (91 and 71.94%, respectively, Figure 8).
Accordingly, A2AR inactivation promotes the acquisition of
classically activated M1 Mfs phenotype. These data also
suggest that CD169 and CD163 antibodies recognize ED1
cells in addition to ED1þ cells.
JunD expression is modulated by A2AR
Behmoaras et al.21 demonstrated that the activator protein-1
transcription factor JunD is a primary determinant of Mf
activation and that it is overexpressed in Wistar-Kyoto
(WKY) rats. Hence, we analyzed JunD mRNA expression in
nephritic rats treated with A2AR agonist or antagonist. A2AR
activation decreased glomeruli JunD expression, whereas
JunD transcript levels were restored by A2AR inactivation
(Figure 9). Because Mf infiltration was different among the
groups, it is probably that JunD expression in the glomeruli
does not reflect the effect of A2AR agonist or A2AR antagonist
on Mf JunD expression. We stimulated peritoneal Mfs from
normal WKY rats with lipopolysaccharide in the presence or
absence of A2AR agonist or A2AR antagonist to determine
their effect on activated Mfs. A2AR activation attenuated Mf
JunD expression; instead, A2AR inactivation increased JunD
expression on activated Mfs (Figure 9). These studies
suggest that A2AR modulates Mf JunD expression to affect
Mf responses.
Modulation of A2AR does not affect antigen-specific humoral
immune response or glomerular immunoglobulin G (IgG)
deposition
To analyze if the systemic humoral immune response could
be affected by A2AR activation or inactivation, we assessed
antigen-specific total rat anti-rabbit IgG serum by enzyme-
linked immunosorbent assay. Total rat anti-rabbit globulin
IgG levels were similar among the groups at different serum
dilutions (Figure 10a and b). In addition, rabbit IgG and rat
IgG glomerular deposition were not different among the
groups (Figure 10c).
DISCUSSION
Our results indicate that activation of adenosine A2A
receptors prevents infiltration of Mf into the kidney, arrests
progression of kidney disease, and inhibits progressive
fibrosis in a model of advanced GN that included fibrosis.
We also have evidence that stimulation of A2AR resulted in
glomerular repair, as noted by a reduction in type III and
type IV collagen deposition in glomeruli at day 20 following
treatment compared with day 14 pretreatment. Additional
benefits of treatment included reduction in deposition of
a-SMA plus restoration of E-cadherin expression throughout
the kidney. Consequently, activation of A2AR could arrest
progression of kidney disease and might even reverse kidney
fibrosis severity.
A principal mechanism by which A2AR activation
mediates kidney protection is by suppressing Mf infil-
tration. Specifically, we have found that Mfs isolated from
nephritic glomeruli express A2AR (ref. 16) and these Mfs
secrete factors that cause tissue injury and fibrosis. Consis-
tent with our findings, others have reported that Mf
depletion can suppress glomerular crescent formation and
reduce proteinuria in anti-GBM GN.7 In addition, Duffield
et al.9 studied mice in which they depleted Mfs at an
established phase of anti-GBM GN. There was a marked
reduction in kidney injury and fibrosis with reduced
ED1
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Control A2AR agonist A2AR antag
Figure 8 |Phenotype of macrophages infiltrating nephritic kidneys. In control rats there was prominent glomerular and tubulo-
interstitial accumulation of macrophages (ED1þ cells), expressing both CD169 and CD163 markers. In rats treated with adenosine 2A
receptor (A2AR) agonist, glomerular and interstitial accumulation of macrophages was markedly reduced, and o50% expressed
CD163. In rats treated with A2AR antagonist, glomerular and interstitial macrophages expressed predominantly CD169 (91 and 71.94%,
respectively).
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myofibroblast infiltrations and Col III plus a decrease in
TIMP-1 mRNA.9
During the development of kidney fibrosis, type I and
type III collagens are found in the kidney interstitium and
the levels increase markedly during the development of
glomerulosclerosis and kidney interstitial fibrosis.22,23 This is
relevant because we have found that deposition of Col I and
Col III was strongly associated with a-SMA-expressing
myofibroblasts (data not shown). The A2AR agonist sig-
nificantly reduced Col I, Col III, and a-SMA deposition. They
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Figure 9 | Expression of JunD determined by RNase protection assay. JunD mRNA expression was attenuated by adenosine 2A receptor
(A2AR) agonist and restored by A2AR antagonist (antag) in the nephritic glomeruli. In activated peritoneal macrophages, A2AR activation
downregulated and A2AR inactivation upregulated JunD mRNA expression.
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Figure 10 | Systemic antigen-specific immune response and glomerular immunoglobulin G (IgG) deposition. Circulating titers
of rat anti-rabbit IgG at serum dilution of (a) 1:20 or (b) 1:100 were not different among the nephritic groups. *Po0.01 vs normal.
(c) Immunofluorescence staining of rabbit IgG and rat IgG. Immunofluorescence staining revealed rabbit IgG and rat IgG binding along the
capillary walls of glomeruli in a linear pattern, with no discernible difference in the intensity among the groups.
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were enhanced by the A2AR antagonist. These observations
agree with reports that myofibroblasts participate in the
synthesis of ECM components.24
To identify mechanisms by which A2AR activation
mediates kidney protection, we determined the expression
of Mf mediators that could be responsible for the deposition
and degradation of ECM. In anti-GBM GN, OPN-1, TSP-1,
and TGF-b1 transcripts were significantly increased in whole
kidneys and A2AR agonists markedly reduced these responses.
These levels were restored or increased in A2AR-antagonist-
treated rats.
TGF-b1 is considered to be a key modulator of kidney
fibrosis as it induces collagen synthesis by fibroblasts. TGF-b1
also induces kidney epithelial cells to undergo epithelial-to-
mesenchymal transition.25,26 In this study treatment with the
A2AR agonist inhibited TGF-b1 expression in association
with reduced deposition of collagens, inhibition of a-SMA
expression, and the restoration of E-cadherin appearance.
Mfs in glomerular crescents express OPN-1, and OPN-1
reportedly contributes to fibrosis.27–29 This is relevant
because we found that A2AR depresses OPN-1 expression.
TSP-1 is a 450-KD glycoprotein that inhibits angiogenesis
and activates latent TFG-b; it is present in progressive kidney
diseases and in models of kidney fibrosis.30–32 In Mfs
isolated from nephritic glomeruli, we found that TGF-b,
OPN, TSP-1, and TIMP-1 are expressed (Figure 6a and b).
The A2AR agonist administration decreased Mfs and
suppressed TGF-b, OPN, TIMP-1, and TSP-1 expression in
whole kidneys. Together, these responses yield a mechanism
by which activation of A2AR will arrest kidney fibrosis.
When we investigated how A2AR agonist markedly reduced
Mf infiltration, we could not find increased apoptotic cells;
however, the expression of MDC/CCL22 was suppressed by
A2AR activation. MDC/CCL22, in contrast to other chemo-
kines, is expressed throughout anti-GBM GN and is the main
chemokine responsible for Mf infiltration in the progressive
phase of this model of GN.10,33 Accordingly, the mechanism
responsible for the reduced Mf infiltration to the kidney is
probably suppression of MDC/CCL22 expression.
A2AR activation could also protect from kidney damage by
affecting Mf phenotype favoring an alternative state that
promotes wound healing and resolution of inflammation.
We found that A2AR inactivation promotes M1 phenotype
enhancement, whereas A2AR activation does not redirect
Mfs toward an M2 phenotype. However, because of the
small number of Mfs in the A2AR-agonist-treated group
(3.14±0.133), it is difficult to interpret the results. In
addition, it is probably that at the time of starting treatment
with the A2AR agonist (day 14), a switch of infiltrative Mfs
toward an M2 phenotype could take place that cannot be
appreciated at the time the rats were killed (day 20).
WKY rats are susceptible to develop crescentic GN.
Recently, Behmoaras et al.21 found that JunD regulates Mf
activation and that its expression levels are critical to the
susceptibility of crescentic GN in WKY rats by determining a
specific Mf phenotype. Accordingly, we tested whether A2AR
could modulate JunD expression. We found that A2AR
activation reduces the expression and that A2AR inactivation
restores the expression of JunD in the glomeruli; in activated
peritoneal Mfs, A2AR agonist inhibits JunD expression
whereas A2AR antagonist increases its expression, suggesting
that inhibition of Mf JunD could be a mechanism to
attenuate Mf activity and kidney injury by A2AR activation.
Importantly, protection from inflammation and tissue
injury by A2AR activation was mainly because of impaired
Mf infiltration/activation into the kidney rather than the
inability to elicit a systemic nephritogenic immune response,
as rat anti-rabbit serum IgG titers demonstrated that treated
rats and untreated rats produce an efficient immune
response. Moreover, there was no difference in the binding
of rabbit or rat IgG to the glomeruli among the groups.
We reported that A2AR activation in the acute phase of the
anti-GBM GN restores the expression of a-actinin-4, a
marker for podocytes, and reduces the expression of a-SMA,
a marker for mesangial cells injury.16 It has also been
reported that activation of A2AR preserves the structure and
function of podocytes.34 In this study we cannot exclude the
possibility that A2AR activation could protect kidneys
through effects on podocytes and/or mesangial cells.
In summary, pharmacological activation of A2AR during
anti-GBM GN attenuates Mf infiltration into the kidney,
suppresses inflammation, arrests kidney disease progression,
and reduces the severity of kidney fibrosis. A2AR represents
a potential new therapeutic for the treatment of advanced
kidney lesions secondary to GN, and may provide new
avenue for the treatment of progressive kidney disease.
MATERIALS AND METHODS
Induction, treatment, and analysis of anti-GBM in WKY rats
Nephrotoxic serum was prepared in rabbits by the method of
Krakower and Greenspon as described in Garcia et al.10 and Feng
et al.35 All animal studies were approved by the institutional animal
care and use committee at Baylor College of Medicine. Male WKY
rats (Harlan Sprague Dawley, Indianapolis, IN), weighing 180–200 g
received one intravenous injection of anti-GBM Ab (325 mg of rabbit
IgG per 100 g body weight). Pharmacological activation of A2AR was
induced with a selective A2A receptor agonist, CGS 21680 (Tocris
Cookson, Ellisville, MO; 1.5mg/kg intraperitoneal twice a day,
n¼ 6). A2AR was inactivated with a selective receptor antagonist,
ZM241385 (Tocris; 2mg/kg intraperitoneal twice a day, n¼ 6) as
described, for a period of 6 days.17 Control rats received the vehicle.
Treatment with the A2AR agonist or antagonist was delayed until
day 14 after the injection of anti-GBM Ab. Urine protein excretion
was measured on timed 24-h specimens at days 13, 15, 17, and 19.
On day 20, blood and kidney tissues were collected. Serum
creatinine was determined using COBRAS INTEGRA Creatinine
plus system (Roche Diagnostics, Indianapolis, IN).
Morphological analysis and immunohistochemical
phenotyping and quantitation of leukocytes
Kidney sections were examined for glomerular hypercellularity,
necrotizing lesions, and formation of glomerular crescents. The
number of crescentic glomeruli per 100 glomeruli of each rat was
calculated and expressed as a percentage.33
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For staining of ED1þ CD8þ , CD4þ , CD169þ (a marker for M1
Mfs), and CD163þ (a marker for M2 Mfs) infiltrates, slides were
reacted with mouse anti-rat CD8 (BD Pharmingen, San Diego, CA),
mouse anti-rat ED-1, mouse anti-rat CD4 (domain 1), mouse anti-
rat CD169, and mouse anti-rat CD163 (AbD Serotec, Raleigh, NC),
and peroxidase-coupled anti-mouse IgG second antibodies. Posi-
tively stained cells per 100 glomeruli of each rat were counted and
expressed per glomerular section.33 All quantitative morphological
analyses were performed in a blinded fashion.
Immunohistochemistry and TUNEL assay
Apoptosis was determined by TUNEL using the ApopTag plus
peroxidase in situ apoptosis detection kit (Millipore, Billerica, MA).
Mfs were stained with anti-rat ED1 Ab. TUNEL and ED1
immunostaining were performed on serial sections.
Measurement of mRNA expression of profibrotic molecules
and cytokines by RNase protection assay in whole kidney
A rat OPN-1 303 bp probe (nucleotide 335–638, accession number
AB001382) was generated by reverse transcriptase-PCR using kidney
tissue. Rat JunD 246 bp probe (nucleotide 397–643, accession
number NM_138875) was generated from bone marrow-derived
Mfs. TSP-1 (388 bp), TIMP-1 (308 bp), MMP-2 (222 bp), bone
morphogenic protein-7 (409 bp), MDC/CCL22 (400 bp), and L-32
(92 bp) riboprobes were generated by PCR as described.35,36 rCK1
(BD Pharmingen) was used to investigate the expression of
cytokines, including TGF-b. From each sample, 3 mg of total RNA
was used for RNase protection assay using a kit (Torrey Pines
Biolabs, East Orange, NJ).35 Phosphoimage quantitation was
performed using the PhosphorImager SI scanning instrument and
ImageQuaNT software (Molecular Dynamics, Sunnyvale, CA).
Preparation and sorting of M/s from nephritic glomeruli and
isolation of normal peritoneal M/s
Inflammatory leukocytes were isolated from the nephritic glomeruli
at day 20 after the injection of anti-GBM Ab as described by
Cook et al.37 with some modifications.33,38 Cell viability wasB90%
as determined by Trypan blue. Mfs were identified by flow sorting
as described38,39 and RNA purified for RNase protection assay to
detect TSP-1, OPN-1, TGF-b, and TIMP-1. Peritoneal Mfs were
collected from normal WKY rats and stimulated with lipopolysac-
charide (5 ng/ml) in the presence or absence of A2AR agonist
(CGS21680, 10 mM) or A2AR antagonist (ZM241385, 10 mM).
17,38,40
Determination of collagen, a-SMA, and E-cadherin deposition
by immunohistochemistry
The primary antibodies used were polyclonal goat anti-human coll I,
anti-human Col III, and anti-human Col IV (Southern Biotech,
Birmingham, AL), plus monoclonal antibodies against human
a-SMA (Clone 1A4, Dako, Carpinteria, CA) and E-cadherin (Clone
DECMA-1, Sigma, St Louis, MO). Secondary antibodies were
peroxidase-coupled rabbit anti-goat or anti-mouse IgG.
Histological morphometry was performed using an image
analysis system consisting of an IBM-compatible computer equip-
ped with a Fast card and a color Sports Camera linked to a Carl
Zeiss (Thornwood, NY) microscope.
Circulating Ab and glomerular IgG deposition
Rat anti-rabbit IgG Ab titers were measured by enzyme-linked
immunosorbent assay using sera that were collected at day 20 after
the induction of nephritis as described.19,41 Bound rat IgG was detected
using peroxidase-conjugated anti-rat IgG (Dako) at 1:1000 and
absorbance reading at 450nm. Normal sera served as negative control.
IgG deposition was determined in kidney frozen sections using
FITC-labeled anti-rabbit IgG (DAKO) or anti-rat IgG (Southern
Biotech) at different dilutions as described.33,38
Statistical method
Statistical analyses were performed using analysis of variance.
Significant differences were analyzed by comparing individual group
means using the unpaired Student’s t-test. A Po0.05 was defined as
statistically significant.
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